Telehealth company Hims & Hers announced on February 5, 2026, plans to launch a cheaper compounded pill version of Novo Nordisk's Wegovy, capitalizing on GLP-1 drug demand.3
Novo Nordisk vowed to sue Hims & Hers over the Wegovy knockoff pill launch.3
FDA and industry face ongoing disputes over compounded semaglutide and tirzepatide; FDA has not yet resolved semaglutide shortage, allowing compounding to continue, unlike tirzepatide.1
FDA Commissioner Robert Califf expressed concerns over compounded and fake GLP-1 drugs like Wegovy lacking safety controls, with warning letters sent to online vendors.47
No direct statements from FDA chief Marty Makary found in recent results, but context involves regulatory scrutiny on compounding amid resolved shortages for some GLP-1s.136
Sources:
1. https://www.fiercepharma.com/pharma/lilly-looks-wade-legal-fracas-between-fda-and-compounders-following-end-tirzepatide-shortage
3. https://kffhealthnews.org/morning-briefing/friday-february-6-2026/
4. https://www.foxbusiness.com/media/fda-chief-sounds-alarm-over-fake-weight-loss-drugs-circulating-online
6. https://www.statnews.com/2024/12/31/key-issues-to-watch-fda-in-2025-compounding-ai-user-fees-food-additives-marty-makary-rfk-jr/
7. https://www.aol.com/news/us-fda-chief-says-very-154030541.html